SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as traders discuss its chart patterns, specifically the EMA and recent dip, suggesting a potential upward movement. Community members are pointing to increased volume and speculation around AI and data infrastructure as potential catalysts. Some are also comparing FIL to other cryptocurrencies, highlighting Filecoin's utility and potential to reclaim previous highs.

Aventus Network

Aventus Network ($AVT) is trending as the community discusses its potential for a breakout, citing its integration with Polkadot, enterprise partnerships, and low market cap. The recent appointment of Dr. Marwan Al Zarouni as a strategic advisor to expand its presence in the UAE is also generating buzz. Traders are closely monitoring volume and potential new exchange listings as possible catalysts.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is experiencing a surge in community interest, driven by discussions around AI integrations and potential for cross-chain applications. Traders are actively discussing entry points, staking rewards, and long-term price potential, with some anticipating a significant rise. The conversation also includes the broader altcoin market recovery and NEAR's position within it.

Literally a dog wif a hat, dogwifhat (WIF) is a meme coin that's part of the ever-growing ecosystem of digital currencies on the Solana blockchain. This token brings a lighthearted twist to cryptocurrency, featuring a playful dog with a hat as its mascot, symbolising a more whimsical approach to the often serious domain of digital finance.

dogwifhat

Dogwifhat ($WIF) is trending as traders express frustration with the token's price action, citing frequent dumps and sideways trading. Many community members are commenting on resistance levels and expressing concerns about potential losses, while others are hoping for a breakout and comparing it to other meme coins. Some traders are speculating on potential catalysts and future price movements, while others suggest the coin is manipulated or doomed to fail.

Avnet, Inc. engages in the provision of distribution and sale of electronic components. It operates through the Electronic Components and Farnell segments. The Electronic Components segment markets and sells semiconductors, interconnect, passive and electromechanical devices, and integrated components. The Farnell segment focuses on the distribution of electronic components and related products to the electronic system design community utilizing multi-channel sales and marketing resources. The company was founded by Charles Avnet in 1921 and is headquartered in Phoenix, AZ.

Avnet Inc.

Avnet ($AVT) is trending amid discussions around its Q1 earnings and future outlook. While the company beat EPS estimates, community members are focused on forward guidance. A new strategic collaboration with Amazon Web Services (AWS) is also generating buzz.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara Inc is trending, driven by discussion around recent earnings and forward guidance. While some express concern over decelerating growth and stock performance, others highlight the company's strong fundamentals, potential for long-term gains, and AI-driven innovation within the IoT sector, especially within fleet operations. There is also interest in potential partnerships and acquisitions, contributing to the stock's current activity.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending as the community discusses its potential as a decentralized cloud and AI hub, drawing comparisons to other blockchains and highlighting its unique technology. Some speculate about institutional interest and potential partnerships, while others caution against chasing the rally and point out its volatile history. Overall, the discussion revolves around ICP's utility and whether it can challenge established players in the tech and crypto space.

Harvest automatically farms the highest yields in DeFi

Harvest Finance

Harvest Finance ($FARM) is trending as traders discuss its low float and potential for significant price movement, especially with the upcoming Bitcoin halving event. The community is actively speculating on price targets, some projecting substantial gains based on its limited supply and historical performance. Discussions also highlight the recent Arbitrum DAO approval, potentially incentivizing yield farming and boosting the token's utility.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amid broader crypto market fluctuations, sparking discussions about its potential to rebound. Community members are debating whether to buy the dip or brace for further declines, with some referencing Elon Musk's past influence and future prospects. Overall, the conversation reflects uncertainty balanced with hope for a resurgence.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos ($XTZ) is trending amid mixed sentiment, with some traders anticipating a pump towards $1 while others foresee a continued downtrend. The community is heavily debating whether $XTZ is a "sucker coin", with discussions focused on potential market manipulation and future price movements. Some traders are also discussing staking and potential benefits from upcoming FED rate cuts on altcoins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."read more...

Pfizer Sweetens Offer For Metsera To $86.25/shr Amid Escalating Bidding War With Novo Nordisk

(RTTNews) - Metsera Inc. (MTSR) announced that it has entered into an amended merger agreement with Pfizer, under which Pfizer will acquire Metsera for up to $86.25 per share. The deal includes...

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's...

Metsera (NASDAQ:MTSR) Trading Up 10.6% - Still a Buy?

Metsera (NASDAQ:MTSR) Trading 10.6% Higher - Here's What Happened...

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call

Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.

Investors Purchase High Volume of Put Options on Metsera (NASDAQ:MTSR)

Metsera Inc. (NASDAQ:MTSR - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock traders purchased 2,401 put options on the company. This represents an increase of...

Tesla Investors Approve Musk Pay Package, Comcast's Sky in Talks to Buy ITV  The Opening Trade 11/7

Tesla shareholders approved a potential $1 trillion compensation package for Chief Executive Officer Elon Musk, the largest payout ever awarded to a corporate leader. Musk would have to meet certain...

<ul class="summary-bullets"><li>The details of the new bid could not be immediately ascertained, FT said.</li><li>Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;</li><li>Pfizer reportedly matched Novo’s last offer late on Wednesday, prompting Novo’s new bid.<br>&nbsp;</li></ul><p>Danish drugmaker Novo Nordisk has reportedly sweetened its bid further for obesity drug maker Metsera amid a rising bidding war with Pfizer.</p><p>The Financial Times<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/52216b29-9f22-4338-85a7-eacfc33103a1"> reported</a> on Thursday, citing people familiar with the matter, that Novo raised its bid after Pfizer matched its last offer, valuing the company at up to $10 billion, late on Wednesday.</p><p>The details of the new bid could not be immediately ascertained, FT said. Pfizer now has two days to match Novo’s bid or let its agreed-upon deal with Metsera fall through, the report stated.&nbsp;</p><h2 class="st-heading-2">Start Of The Bidding War</h2><p>Novo Nordisk first announced last week that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera determined that Novo’s bid was superior and gave Pfizer a certain number of days to negotiate the terms of their agreement. &nbsp;</p><p>On Monday, Metsera said that it has received revised bids from both Pfizer and Novo, valuing the company at up to $8.1 billion and $10 billion, respectively. Pfizer reportedly matched Novo’s offer late on Wednesday, prompting Novo’s new bid.</p><p>Pfizer had requested a temporary restraining order from the Delaware Chancery Court last week to prevent Metsera from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. However, the court denied the request on Wednesday. Pfizer, however, said that it intends to pursue further litigation and expressed confidence in the merit of claims that Metsera has acted in breach of its contractual obligations. Metsera, on its side, dismissed Pfizer’s arguments as “nonsense.”</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p><a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> soared 14% at the time of writing. On Stocktwits, retail sentiment around MTSR stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.</p><p>MTSR stock has more than tripled this year.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnson-newly-acquired-antipsychotic-drug-approved-by-fda-for-major-depressive-disorder/cL2tuwZRERN">Johnson &amp; Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further

According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through. 

Equity

<ul class="summary-bullets"><li>Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.</li><li>The court decision follows Metsera’s board reaffirming Novo’s revised $86.20-per-share offer as superior to Pfizer’s $8.1 billion counterproposal.</li><li>Pfizer vowed to continue its legal and antitrust challenges in Delaware federal court.</li></ul><p>Novo Nordisk’s U.S.-listed shares rose Wednesday, ending an 11-session losing streak, after a Delaware judge rejected Pfizer's request to block the Danish company’s $10 billion acquisition of obesity-drug startup Metsera Inc.</p><p>Delaware Chancery Judge Morgan Zurn said Pfizer’s objections didn’t warrant delaying the transaction and found no evidence Metsera’s board acted in bad faith when it labeled Novo’s offer “superior.” The ruling allows Novo to proceed with the deal, which topped Pfizer’s earlier $4.9 billion agreement announced in September, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-05/pfizer-loses-legal-bid-to-temporarily-block-novo-s-metsera-offer">report</a>.</p><h2 class="st-heading-2"><strong>Revised Offers Raise The Stakes</strong></h2><p>On Tuesday, Metsera said it received a revised offer from Novo valuing the company at up to $86.20 per share, or about $10 billion. The new proposal includes $62.20 per share in cash, up from $56.50 in the original bid, plus contingent value rights worth up to $24.00 per share if certain milestones are achieved.</p><p>Pfizer also revised its terms, increasing upfront consideration to $60 per share and trimming the contingent payout to $10 per share, valuing its bid at roughly $8.1 billion. Despite the adjustment, Metsera’s board reaffirmed Novo’s offer as superior and gave Pfizer two business days to counter before terminating its merger agreement.</p><h2 class="st-heading-2"><strong>Pfizer Vows To Keep Fighting</strong></h2><p>Pfizer said the ruling “fails to address the legal issues raised” and vowed to continue litigation in Delaware federal court, calling Novo’s bid “an unprecedented and illegal scheme to circumvent antitrust scrutiny.” The company alleges Novo’s move is designed to protect its dominance in the GLP-1 obesity-drug space by neutralizing a future competitor.</p><p>Novo countered that the court’s ruling validates its approach and serves shareholders’ best interests. Its offer, which includes both upfront and milestone-based payments, aims to bring Metsera’s experimental weight-loss portfolio, which is a potential rival to Ozempic and Wegovy, under its umbrella.</p><h2 class="st-heading-2"><strong>FTC Flags Premerger Concerns</strong></h2><p>The U.S. Federal Trade Commission warned that Novo’s offer could breach the Hart-Scott-Rodino Act if completed without premerger review. In a Nov. 4 letter, the FTC said the structure of Novo’s bid, which grants substantial upfront payments before regulatory approval, could reduce Metsera’s independence and incentive to pursue its drug pipeline.</p><h2 class="st-heading-2"><strong>Stocktwits Bulls Cheer, Bears Question The Deal</strong></h2><p>On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid a 159% jump in 24-hour message volume.</p><figure class="image"><img style="aspect-ratio:964/138;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_016bd02a5d.webp" alt="nvo ss.jpg" width="964" height="138"><figcaption>NVO sentiment and message volume as of November 5 | Source: Stocktwits</figcaption></figure><p>One user suggested that better days could be close, urging others to “hold strong.”</p><p><stembedurl>https://stocktwits.com/RunGoodStreakAlive/message/635121830</stembedurl></p><p>Another user, however, questioned whether Novo’s management understood investor sentiment, noting that Pfizer’s stock tends to rise each time it appears closer to reclaiming the Metsera deal, suggesting that shareholders aren’t convinced by Novo’s acquisition push.</p><p><stembedurl>https://stocktwits.com/GreenHawkz/message/635102183</stembedurl></p><p><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 43% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal

Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.

<ul class="summary-bullets"><li>Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.</li><li>Q3 sales rose 5% to 75 billion kroner, with Wegovy revenue up 18% but below expectations.</li><li>UBS said a potential $149-per-month U.S. pricing deal for obesity drugs could expand Medicare access but also weigh on Novo Nordisk’s global pricing power.</li></ul><p>Novo Nordisk’s new CEO, Mike Doustdar, cut the company’s profit forecast after slower Wegovy sales and rising competition in the obesity-drug market. The downgrade comes as the firm pursues a $10 billion bid for Metsera and, reportedly, nears a White House deal that could cap obesity-drug prices at $149 a month in exchange for Medicare coverage.</p><h2 class="st-heading-2"><strong>Earnings Review</strong></h2><p>Novo Nordisk, the maker of Wegovy and Ozempic, lowered its full-year guidance on Wednesday, signaling a rocky start for new CEO Mike Doustdar. The company now expects operating profit growth of 4%–7% in local currencies for 2025, down from an earlier 10%–16%, and sales growth of 8%–11%, below the previous 8%–14% range.</p><p>Doustdar attributed the cut to “lower growth expectations for our GLP-1 treatments,” adding that the company will accelerate efforts “to compete better in dynamic and increasingly competitive markets.”</p><p>Third-quarter sales rose 5 % to 75 billion Danish crowns ($11.7 billion). Wegovy sales climbed 18% to 20.35 billion Danish crowns, but missed expectations of 21.35 billion Danish crowns, as pricing pressure and rising competition from Eli Lilly’s Zepbound weighed on performance.</p><h2 class="st-heading-2"><strong>New CEO Faces Early Test</strong></h2><p>Doustdar, who took charge in August, faces one of Novo Nordisk’s toughest transitions in years. The company’s shares have dropped 43% in 2025, as pricing wars, U.S. policy headwinds, and management reshuffles have dented investor confidence in what was once Europe’s most valuable firm.</p><p>Novo Nordisk said its company-wide restructuring aims to streamline operations and reinvest for growth, with a renewed focus on obesity treatments.</p><h2 class="st-heading-2"><strong>Metsera Bid And Legal Battles</strong></h2><p>The Danish drugmaker’s revised $10 billion offer for U.S. obesity biotech Metsera has intensified its rivalry with Pfizer, which has filed two lawsuits alleging anticompetitive behavior.&nbsp;</p><p>Novo Nordisk dismissed the claims as “false and without merit.” Metsera said Novo’s latest proposal was “superior” to Pfizer’s, but the escalating bid raises investor concerns about cost discipline amid narrowing profit growth.</p><h2 class="st-heading-2"><strong>US Pricing Talks</strong></h2><p>Adding to the uncertainty, UBS said in a research note that Novo Nordisk and Eli Lilly’s supposed deal with the White House on obesity-drug pricing would cap prices at $149 per month for the lowest dose in exchange for Medicare coverage.</p><p>The investment bank described its stance as “mixed,” while Medicare inclusion could drive volume upside, the $149 price level represents a major discount versus global obesity-drug pricing. UBS, which rates Novo Nordisk shares as ‘Neutral’ with a 340 Danish crowns price target, said investors will watch whether the deal includes the Inflation Reduction Act’s Part D drug-price negotiation for semaglutide, and whether Novo has offered deep Wegovy discounts to preserve Ozempic pricing.</p><h2 class="st-heading-2"><strong>Investor Sentiment</strong></h2><p>Before the earnings announcement, Bourbon Capital&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/BourbonCap/status/1985846608320188641">noted in a post on X</a> that the company’s earnings yield and return on capital were considered "attractive," signaling confidence in Novo’s long-term profitability.</p><h2 class="st-heading-2"><strong>Stocktwits Users Debate Novo Nordisk’s Post-Earnings Dip</strong></h2><p>On Stocktwits, retail sentiment for Novo Nordisk was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:966/139;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_fe9afe78a9.webp" alt="nvo ss.jpg" width="966" height="139"><figcaption>NVO sentiment and message volume as of November 4 | Source: Stocktwits</figcaption></figure><p>One user said approval of Novo Nordisk’s GLP-1 pill in the U.S., combined with its recent acquisitions, could “make this stock explode,” predicting that the post-earnings dip would be quickly bought once European markets opened.</p><p><stembedurl>https://stocktwits.com/GetRektDoggy/message/634975033</stembedurl></p><p>Another user said the results amounted to a “small miss as expected,” noting that guidance had merely narrowed and speculated&nbsp;on the market’s move ahead of the Trump deal.</p><p><stembedurl>https://stocktwits.com/NorthstarT1D/message/634973987</stembedurl></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Novo Nordisk Q3 earnings and revenue climbed by double-digit percentages.

Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?

Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Stocktwits

Stocktwits Polls

Metsera Inc

Metsera is trending due to Pfizer's $10 billion acquisition, sparking community discussion about Novo Nordisk's failed bid and potential next moves. Community members are debating the deal's implications for pipeline competition, potential short squeezes, and the broader obesity treatment market. The focus remains on the bidding war and speculation around future acquisitions in the pharmaceutical sector.

Current Price	$89.00
Prev Close	$81.55
Open	$81.50
Dividend Yield	N/A
50-Day Moving Average	$49.99
Beta	1.72
Avg. Volume	1.88M
PE Ratio	N/A

52-Week High	$83.86
52-Week Low	$12.30
Market Capitalization	$8.76B
EPS (Annual)	-$1.99
Price to Book	19.42
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MTSR News

MTSRMetsera Inc